DÄ internationalArchive44/2019Nuclear imaging in the diagnosis of clinically uncertain parkinsonian syndromes

Review article

Nuclear imaging in the diagnosis of clinically uncertain parkinsonian syndromes

Dtsch Arztebl Int 2019; 116: 747-54. DOI: 10.3238/arztebl.2019.0747

Buchert, R; Buhmann, C; Apostolova, I; Meyer, P T; Gallinat, J

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie und Nuklearmedizin, Universitätsklinikum Hamburg-Eppendorf: Dr. rer. nat. Ralph Buchert, PD Dr. med. Ivayla Apostolova
Klinik und Poliklinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf: Prof. Dr. med. Carsten Buhmann
Klinik für Nuklearmedizin, Universitätsklinikum Freiburg: Prof. Dr. med. Dr. nat. med. Philipp T. Meyer
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf: Prof. Dr. med. Jürgen Gallinat
1.DGN, AWMF: S3-Leitlinie „Idiopathisches Parkinson-Syndrom“. AWMF-Register-Nummer: 030–010. 2016. www.awmf.org/uploads/tx_szleitlinien/030–010l_S3_Parkinson_Syndrome_Idiopathisch_2016–06.pdf (last accessed on 3 September 2019).
2.Postuma RB, Berg D, Stern M, et al.: MDS clinical diagnostic criteria for Parkinson‘s disease. Mov Disord 2015; 30: 1591–601 CrossRef MEDLINE
3.Gilman S, Wenning GK, Low PA, et al.: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–6 CrossRef MEDLINE PubMed Central
4.Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G: Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 2016; 86: 566–76 CrossRef MEDLINE
5.Meyer PT, Frings L, Hellwig S: Nuklearmedizinische Differenzialdiagnostik der Parkinson-Syndrome: Update 2016. Der Nuklearmediziner 2016; 39: 245–58 CrossRef
6.Neumeyer JL, Wang SY, Gao YG, et al.: N-Omega-Fluoroalkyl Analogs of
(1r)-2-Beta-Carbomethoxy-3-Beta-(4-Iodophenyl)-Tropane (Beta-Cit) – radiotracers for positron emission tomography and single-photon emission computed-tomography imaging of dopamine transporters. J Med Chem 1994; 37: 1558–61 CrossRef MEDLINE
7.Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W: Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 2014; 29: 1767–73 CrossRef MEDLINE
8.Colloby SJ, McParland S, O‘Brien JT, Attems J: Neuropathological correlates of dopaminergic imaging in Alzheimer‘s disease and Lewy body dementias. Brain 2012; 135: 2798–808 CrossRef MEDLINE
9.Perju-Dumbrava LD, Kovacs GG, Pirker S, et al.: Dopamine transporter imaging in autopsy-confirmed parkinson‘s disease and multiple system atrophy. Movement Disord 2012; 27: 65–71 CrossRef MEDLINE
10.Booij J, Dubroff J, Pryma D, et al.: Diagnostic performance of the visual reading of (123)I-Ioflupane SPECT images with or without quantification in patients with movement disorders or dementia. J Nucl Med 2017; 58: 1821–6 CrossRef MEDLINE
11.Seibyl JP, Kupsch A, Booij J, et al.: Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. J Nucl Med 2014; 55: 1288–96 CrossRef MEDLINE
12.Albert NL, Unterrainer M, Diemling M, et al.: Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging 2016; 43: 1315–22 CrossRef MEDLINE
13.Lee I, Kim JS, Park JY, et al.: Head-to-head comparison of (18)F-FP-CIT and (123) I-FP-CIT for dopamine transporter imaging in patients with Parkinson‘s disease: a preliminary study. Synapse 2018; 72: e22032 CrossRef MEDLINE
14.Kordower JH, Olanow CW, Dodiya HB, et al.: Disease duration and the integrity of the nigrostriatal system in Parkinson‘s disease. Brain 2013; 136: 2419–31 CrossRef MEDLINE PubMed Central
15.Marshall VL, Reininger CB, Marquardt M, et al.: Parkinson‘s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009; 24: 500–8 CrossRef MEDLINE
16.Pirker W, Djamshidian S, Asenbaum S, et al.: Progression of dopaminergic degeneration in Parkinson‘s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002; 17: 45–53 CrossRef MEDLINE
17.Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM: The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson‘s disease or clinically uncertain parkinsonism: a systematic review. Ejnmmi Res 2015; 5: 12 CrossRef MEDLINE PubMed Central
18.Marek KL, Jennings DL, Seibyl JP, Grp PS: Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 2005;64(suppl 1): Abstract 274.
19.Batla A, Erro R, Stamelou M, et al.: Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Mov Disord 2014; 29: 1820–5 CrossRef MEDLINE
20.Hickey PT, Kuchibhatla M, Scott B, Gauger L, Stacy MA: Dopamine transporter imaging has no impact on functional outcomes in de novo probable Parkinson‘s disease. J Parkinson Dis 2017; 7: 279–87 CrossRef MEDLINE
21.Berardelli A, Wenning GK, Antonini A, et al.: EFNS/MDS-ES recommendations for the diagnosis of Parkinson‘s disease. Eur J Neurol 2013; 20: 16–34 CrossRef MEDLINE
22.NICE: Parkinson’s disease in adults. National Institute for Health and Care Excellence (NICE) guideline [NG71], 2017. www.nice.org.uk/guidance/ng71 (last accessed on 3 September 2019).
23.Catafau AM, Tolosa E, Da TCUPSSG: Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004; 19: 1175–82 CrossRef MEDLINE
24.Booij J, Speelman JD, Horstink MW, Wolters EC: The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266–72 CrossRef MEDLINE
25.Hellwig D, Marienhagen J, Menhart K, Grosse J: [Nuclear medicine in Germany. Updated key data and trends from official statistics]. Nuklearmedizin 2017; 56: 55–68 CrossRef MEDLINE
26.Van Laere K, Everaert L, Annemans L, Gonce M, Vandenberghe W, Vander Borght T: The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2008; 35: 1367–76 CrossRef MEDLINE
27.Kupsch AR, Bajaj N, Weiland F, et al.: Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosur Ps 2012; 83: 620–8 CrossRef MEDLINE
28.Grosset DG, Tatsch K, Oertel WH, et al.: Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123I injection (DaTscan). J Nucl Med 2014; 55: 1281–7 CrossRef MEDLINE
29.Booij J, Sokole EB, Stabin MG, Janssen AGM, de Bruin K, van Royen EA: Human biodistribution and dosimetry of [I-123]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998; 25: 24–30 CrossRef
30.Booij J, Kemp P: Dopamine transporter imaging with [I-123]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol I 2008; 35: 424–38 CrossRef MEDLINE
31.Tatsch K, Buchert R, Bartenstein P, et al.: Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCANTM). Nuklearmedizin 2019; 58: 5–16 CrossRef MEDLINE
32.Meyer PT, Frings L, Rucker G, Hellwig S: (18)F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 2017; 58: 1888–98 CrossRef MEDLINE
33.Eckert T, Barnes A, Dhawan V, et al.: FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26: 912–21 CrossRef MEDLINE
34.Hellwig S, Amtage F, Kreft A, et al.: [18F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79: 1314–22 CrossRef MEDLINE
35.Niethammer M, Tang CC, Feigin A, et al.: A disease-specific metabolic brain network associated with corticobasal degeneration. Brain 2014; 137: 3036–46 CrossRef MEDLINE PubMed Central
36.Pilotto A, Premi E, Caminiti SP, et al.: Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. Neurology 2018; 90: E1029–E37 CrossRef MEDLINE
37.Hellwig S, Frings L, Amtage F, et al.: 18F-FDG PET Is an early predictor of overall survival in suspected atypical parkinsonism. J Nucl Med 2015; 56: 1541–6 CrossRef MEDLINE
38.Walker Z, Gandolfo F, Orini S, et al.: Clinical utility of FDG PET in Parkinson‘s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging 2018; 45: 1534–45 CrossRef MEDLINE PubMed Central
39.Whitwell JL, Hoglinger GU, Antonini A, et al.: Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 2017; 32: 955–71 CrossRef MEDLINE PubMed Central
40.Buchert R, Lange C, Apostolova I, Meyer PT: Dopamintransporter-SPECT mit [123I]FP-CIT: Empfehlungen für die visuelle Beurteilung. Der Nuklearmediziner 2015; 38: 40–7 CrossRef
e1.Hoglinger GU, Respondek G, Stamelou M, et al.: Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society Criteria. Movement Disord 2017; 32: 853–64 CrossRef MEDLINE PubMed Central
e2.Armstrong MJ, Litvan I, Lang AE, et al.: Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80: 496–503 CrossRef MEDLINE PubMed Central
e3.Grosset D, Taurah L, Burn DJ, et al.: A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson‘s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007; 78: 465–9 CrossRef MEDLINE PubMed Central
e4.Diaz NL, Waters CH: Current strategies in the treatment of Parkinson‘s disease and a personalized approach to management. Expert Rev Neurother 2009; 9: 1781–9 CrossRef MEDLINE
e5.Global Parkinson‘s Disease Survey Steering Committee: Factors impacting on quality of life in Parkinson‘s disease: results from an international survey. Mov Disord 2002; 17: 60–7 CrossRef MEDLINE
e6.Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU: The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int 2016; 113: 61–9 CrossRef MEDLINE PubMed Central
e7.Koga S, Aoki N, Uitti RJ, et al.: When DLB, PD, and PSP masquerade as MSA. An autopsy study of 134 patients. Neurology 2015; 85: 404–12 CrossRef MEDLINE PubMed Central
e8.Koga S, Kouri N, Walton RL, et al.: Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica 2018; 136: 389–404 CrossRef MEDLINE PubMed Central
e9.Knudsen K, Borghammer P: Imaging the Autonomic Nervous System in Parkinson‘s Disease. Curr Neurol Neurosci Rep 2018; 18: 79 CrossRef MEDLINE
e10.Dickson DW: Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246 Suppl 2: II6–15 CrossRef MEDLINE
e11.Dickson DW, Bergeron C, Chin SS, et al.: Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61: 935–46 CrossRef MEDLINE
e12.Piggott MA, Marshall EF, Thomas N, et al.: Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer‘s and Parkinson‘s diseases: rostrocaudal distribution. Brain 1999; 122 (Pt 8): 1449–68 CrossRef MEDLINE
e13.Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP: Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995; 58: 160–6 CrossRef MEDLINE PubMed Central
e14.Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415–55 CrossRef
e15.Niznik HB, Fogel EF, Fassos FF, Seeman P: The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991; 56: 192–8 CrossRef MEDLINE
e16.Fazio P, Svenningsson P, Cselenyi Z, Halldin C, Farde L, Varrone A: Nigrostriatal dopamine transporter availability in early Parkinson‘s disease. Mov Disord 2018; 33: 592–9 CrossRef MEDLINE
e17.Lee CS, Samii A, Sossi V, et al.: In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson‘s disease. Ann Neurol 2000; 47: 493–503 CrossRef
e18.Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V: Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 2017; 88: 1461–7 CrossRef MEDLINE
e19.Honkanen EA, Saari L, Orte K, et al.: No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson‘s disease. Mov Disord 2019; doi: 10.1002/mds.27777. [Epub ahead of print] CrossRef MEDLINE
e20.Seibyl JP, Marek K, Sheff K, et al.: Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson‘s patients. J Nucl Med 1998; 39: 1500–8.
e21.Van Laere K, De Ceuninck L, Dom R, et al.: Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 2004; 31: 1119–27 CrossRef MEDLINE
e22.Kim HJ, Im JH, Yang SO, et al.: Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson‘s disease subjects. J Nucl Med 1997; 38: 1703–11.
e23.Fischman AJ, Bonab AA, Babich JW, et al.: Rapid detection of Parkinson‘s disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998; 29: 128–41 CrossRef
e24.Ziebell M: Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT. Dan Med Bull 2011; 58: B4279.
e25.Andringa G, Drukarch B, Bol JG, et al.: Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson‘s disease. Neuroimage 2005; 26: 1150–8 CrossRef MEDLINE
e26.Alvarez-Fischer D, Blessmann G, Trosowski C, et al.: Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson‘s disease. Neuroimage 2007; 38: 5–12 CrossRef MEDLINE
e27.Back S, Raki M, Tuominen RK, Raasmaja A, Bergstrom K, Mannisto PT: High correlation between in vivo [123I]beta-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats. Ejnmmi Res 2013; 3: 46 CrossRef MEDLINE PubMed Central
e28.Gleave JA, Farncombe TH, Saab C, Doering LC: Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson‘s. Nucl Med Biol 2011; 38: 741–9 CrossRef MEDLINE
e29.Ashkan K, Wallace BA, Mitrofanis J, et al.: SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson‘s disease. Parkinsonism Relat Disord 2007; 13: 266–75 CrossRef MEDLINE
e30.Tian L, Karimi M, Brown CA, Loftin SK, Perlmutter JS: In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment. Brain Res 2014; 1571: 49–60 CrossRef MEDLINE PubMed Central
e31.Karimi M, Tian L, Brown CA, et al.: Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013; 73: 390–6 CrossRef MEDLINE PubMed Central
e32.Papathanasiou N, Rondogianni P, Chroni P, et al.: Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies. Ann Nucl Med 2012; 26: 234–40 CrossRef MEDLINE
e33.Ahmed A, Huang JB, Chen K, Zubeldia JM, Booij J, Vijayakumar V: [I-123]Ioflupane imaging in Caucasians and non-Caucasians: are there any differences? J Neurol Sci 2018; 395: 159–63 CrossRef MEDLINE
e34.Makinen E, Joutsa J, Johansson J, Maki M, Seppanen M, Kaasinen V: Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism. J Neural Transm (Vienna) 2016; 123: 1309–18 CrossRef MEDLINE
e35.Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL: Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson‘s disease and healthy controls. Eur J Nucl Med Mol Imaging 2009; 36: 454–62 CrossRef MEDLINE
e36.Jakobson Mo S, Axelsson J, Jonasson L, et al.: Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT-a clinical comparison. Ejnmmi Res 2018; 8: 100 CrossRef MEDLINE PubMed Central
e37.Marek K, Seibyl J, Eberly S, et al.: Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014; 82: 1791–7 CrossRef MEDLINE PubMed Central
e38.Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA: Time trends in the incidence of Parkinson disease. JAMA Neurol 2016; 73: 981–9 CrossRef MEDLINE PubMed Central
e39.Oravivattanakul S, Benchaya L, Wu G, et al.: Dopamine Transporter (DaT) Scan utilization in a movement disorder center. Mov Disord Clin Pract 2016; 3: 31–5 CrossRef MEDLINE PubMed Central
e40.Vlaar AM, de Nijs T, Kessels AG, et al.: Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59: 258–66 CrossRef MEDLINE
e41.Dodel RC, Hoffken H, Moller JC, et al.: Dopamine transporter imaging and SPECT in diagnostic workup of Parkinson‘s disease: a decision-analytic approach. Movement Disord 2003; 18: S52–S62 CrossRef MEDLINE
e42.Bruggenjurgen B, Smala A, Chambers M: Cost-effectiveness of non-invasive imaging in the diagnosis of Parkinsonism. Value Health 2005; 8: Aabstract 15 CrossRef
e43.Busca R, Antonini A, Lopatriello S, Berto P: Economic evaluation of SPECT-DaTSCAN in the diagnosis of patients with clinically uncertain Parkinsonism in Italy. Value Health 2005; 8: Abstract 14 CrossRef
e44.Rajput AH, Rozdilsky B, Rajput A: Accuracy of clinical diagnosis in parkinsonism—a prospective study. Can J Neurol Sci 1991; 18: 275–8 CrossRef MEDLINE
e45.Iranzo A, Santamaria J, Valldeoriola F, et al.: Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 2017; 82: 419–28 CrossRef MEDLINE
e46.Postuma RB, Iranzo A, Hu M, et al.: Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019; 142: 744–59 CrossRef MEDLINE PubMed Central
e47.Chahine LM, Iranzo A, Fernandez-Arcos A, et al.: Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder. NPJ Parkinsons Dis 2019; 5: 2 CrossRef MEDLINE PubMed Central
e48.Meles SK, Vadasz D, Renken RJ, et al.: FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder. Mov Disord 2017; 32: 1482–6 CrossRef MEDLINE PubMed Central
e49.Geisler S, Beindorff N, Cremer M, et al.: Characterization of [I-123]FP-CIT binding to the dopamine transporter in the striatum of tree shrews by quantitative in vitro autoradiography. Synapse 2015; 69: 497–504 CrossRef MEDLINE
e50.Fowler JS, Volkow ND, Wang GJ, Gatley SJ, Logan J: [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001; 28: 561–72 CrossRef
e51.Bundesamt für Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte für nuklearmedizinische Verfahren. Salzgitter: Bundesamt für Strahlenschutz 2012. www.bfs.de/DE/themen/ion/anwendung-medizin/diagnostik/referenzwerte/referenzwerte_node.html (last accessed on 3 September 2019.)
e52.Coon EA, Sletten DM, Suarez MD, et al.: Clinical features and autonomic testing predict survival in multiple system atrophy. Brain 2015; 138: 3623–31 CrossRef MEDLINE PubMed Central
e53.Wenning GK, Litvan I, Jankovic J, et al.: Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64: 184–9 CrossRef MEDLINE PubMed Central
e54.Brigo F, Matinella A, Erro R, Tinazzi M: [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson‘s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol 2014; 21: 1369–e90 CrossRef MEDLINE
e55.Thomsen G, Knudsen GM, Jensen PS, et al.: No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res 2013; 3: 39 CrossRef MEDLINE PubMed Central
e56.Kaasinen V, Gardberg M, Roytta M, Seppanen M, Paivarinta M: Normal dopamine transporter SPECT in neuropathologically confirmed corticobasal degeneration. J Neurol 2013; 260: 1410–1 CrossRef MEDLINE
e57.O‘Sullivan SS, Burn DJ, Holton JL, Lees AJ: Normal dopamine transporter single photon-emission CT scan in corticobasal degeneration. Mov Disord 2008; 23: 2424–6 CrossRef MEDLINE
e58.Ceravolo R, Rossi C, Cilia R, et al.: Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. Parkinsonism Relat Disord 2013; 19: 557–9 CrossRef MEDLINE
e59.Tissot H, Frismand S, Marie PY, Gospodaru N, Verger A: 123I-FP-CIT-SPECT in encephalitis involving substantia nigra. Clin Nucl Med 2016; 41: e445–6 CrossRef MEDLINE
e60.Peña E, Fernandez C: Abnormal DAT SCAN in a patient with parkinsonism after a midbrain ischemic lesion. Mov Disord 2012; 27: 205 CrossRef MEDLINE
e61.Kaasinen V, Kankare T, Joutsa J, Vahlberg T: Presynaptic striatal dopaminergic function in atypical parkinsonisms: a meta-analysis of imaging studies. J Nucl Med 2019; pii: jnumed.119.227140. doi: 10.2967/jnumed.119.227140. [Epub ahead of print] CrossRef MEDLINE
e62.Kadekaro M, Crane AM, Sokoloff L: Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc Natl Acad Sci USA 1985; 82: 6010–3 CrossRef MEDLINE PubMed Central
e63.Sokoloff L: Energetics of functional activation in neural tissues. Neurochem Res 1999; 24: 321–9 CrossRef MEDLINE
e64.Harris JJ, Jolivet R, Attwell D: Synaptic energy use and supply. Neuron 2012; 75: 762–77 CrossRef MEDLINE
e65.Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE: A diagnostic approach in Alzheimer‘s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238–48.
e66.Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith C, Frackowiak RSJ: Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 2: 189–210 CrossRef
e67.Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE: Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 1996; 198: 837–43 CrossRef MEDLINE
e68.Hoglinger GU: Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders? No. Mov Disord Clin Prac 2018; 5: 141–4 CrossRef MEDLINE PubMed Central
e69.Hoglinger GU, Respondek G, Kovacs GG: New classification of tauopathies. Rev Neurol (Paris) 2018; 174: 664–8 CrossRef MEDLINE
e70.Ling H, Macerollo A: Is it useful to classify PSP and CBD as different disorders? Yes. Mov Disord Clin Prac 2018; 5: 145–8 CrossRef MEDLINE PubMed Central
e71.Hoglinger GU, Kassubek J, Csoti I, et al.: Differentiation of atypical Parkinson syndromes. J Neural Transm 2017; 124: 997–1004 CrossRef MEDLINE
e72.Bohnen NI, Koeppe RA, Minoshima S, et al.: Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52: 848–55 CrossRef MEDLINE
e73.Zalewski N, Botha H, Whitwell JL, Lowe V, Dickson DW, Josephs KA: FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol 2014; 261: 710–6 CrossRef MEDLINE
e74.Cordato NJ, Halliday GM, McCann H, et al.: Corticobasal syndrome with tau pathology. Mov Disord 2001; 16: 656–67 CrossRef MEDLINE
e75.Josephs KA, Duffy JR, Strand EA, et al.: Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129: 1385–98 CrossRef MEDLINE PubMed Central
e76.Klein RC, de Jong BM, de Vries JJ, Leenders KL: Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson‘s disease. Mov Disord 2005; 20: 1021–30 CrossRef MEDLINE
e77.Tetzloff KA, Duffy JR, Strand EA, et al.: Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase 2018; 24: 111–20 CrossRef MEDLINE PubMed Central
e78.Kaasinen V: Ipsilateral deficits of dopaminergic neurotransmission in Parkinson‘s disease. Ann Clin Transl Neurol 2016; 3: 21–6 CrossRef MEDLINE PubMed Central
e79.Kaasinen V, Vahlberg T: Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol 2017; 82: 873–82 CrossRef MEDLINE
e80.Apostolova I, Taleb DS, Lipp A, et al.: Utility of follow-up dopamine transporter SPECT with 123I-FP-CIT in the diagnostic workup of patients with clinically uncertain parkinsonian syndrome. Clin Nucl Med 2017; 42: 589–94 CrossRef MEDLINE
e81.Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD: Differentiating multiple system atrophy from Parkinson‘s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosur Ps 2002; 73: 517–23 CrossRef MEDLINE PubMed Central
e82.Armstrong MJ, Weintraub D: The case for antipsychotics in dementia with Lewy bodies. Mov Disord Clin Pract 2017; 4: 32–5 CrossRef MEDLINE PubMed Central
e83.Fujimi K, Sasaki K, Noda K, et al.: Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: The hisayama study. Brain Pathol 2008; 18: 317–25 CrossRef PubMed Central
e84.Hogan DB, Fiest KM, Roberts JI, et al.: The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci 2016; 43: S83–S95 CrossRef MEDLINE
e85.McKeith I, O‘Brien J, Walker Z, et al.: Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6: 305–13 CrossRef
e86.Walker Z, Jaros E, Walker RW, et al.: Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007; 78: 1176–81 CrossRef MEDLINE PubMed Central
e87.McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C: Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev 2015; 1: CD010633 CrossRef
e88.Walker RW, Walker Z: Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Mov Disord 2009; 24 (Suppl 2): S754–9 CrossRef MEDLINE
e89.Thomas AJ, Attems J, Colloby SJ, et al.: Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 2017; 88: 276–83 CrossRef MEDLINE PubMed Central
e90.Beach TG, Adler CH, Lue L, et al.: Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009; 117: 613–34 CrossRef MEDLINE PubMed Central
e91.van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW: [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2016; 43: 1060–6 CrossRef MEDLINE PubMed Central
e92.Jung Y, Jordan LG, 3rd, Lowe VJ, et al.: Clinicopathological and (123)I-FP-CIT SPECT correlations in patients with dementia. Ann Clin Transl Neurol 2018; 5: 376–81 CrossRef MEDLINE PubMed Central
e93.Lloyd JJ, Petrides G, Donaghy PC, et al.: A new visual rating scale for Ioflupane imaging in Lewy body disease. Neuroimage Clin 2018; 20: 823–9 CrossRef MEDLINE PubMed Central
e94.Sonni I, Ratib O, Boccardi M, et al.: Clinical validity of presynaptic dopaminergic imaging with (123)I-ioflupane and noradrenergic imaging with (123)I-MIBG in the differential diagnosis between Alzheimer‘s disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiol Aging 2017; 52: 228–42 CrossRef MEDLINE
e95.Morgan S, Kemp P, Booij J, et al.: Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry 2012; 83: 1063–70 CrossRef MEDLINE
e96.McKeith IG, Boeve BF, Dickson DW, et al.: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89: 88–100 CrossRef MEDLINE PubMed Central
e97.Ba F, Martin WR: Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord 2015; 21: 87–94 CrossRef MEDLINE
e98.Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE: Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007; 7: 27 CrossRef MEDLINE PubMed Central
e99.O‘Brien JT, Oertel WH, McKeith IG, et al.: Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open 2014; 4: e005122 CrossRef MEDLINE PubMed Central
e100.Parkinson Study Group: A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55: 1540–7 CrossRef MEDLINE
e101.Benamer TS, Patterson J, Grosset DG, et al.: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15: 503–10 CrossRef
e102.Weng YH, Yen TC, Chen MC, et al.: Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson‘s disease from healthy subjects. J Nucl Med 2004; 45: 393–401.
e103.Jakobson Mo S, Linder J, Forsgren L, Riklund K: Accuracy of visual assessment of dopamine transporter imaging in early Parkinsonism. Mov Disord Clin Pract 2015; 2: 17–23 CrossRef MEDLINE PubMed Central
e104.Gayed I, Joseph U, Fanous M, et al.: The impact of DaTscan in the diagnosis of Parkinson disease. Clin Nucl Med 2015; 40: 390–3 CrossRef MEDLINE
e105.Werner RA, Marcus C, Sheikhbahaei S, et al.: Visual and semiquantitative accuracy in clinical baseline 123I-Ioflupane SPECT/CT imaging. Clinical Nuclear Medicine 2019; 44: 1–3 CrossRef MEDLINE
e106.Buchert R, Lange C, Spehl TS, et al.: Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting. EJNMMI Res 2019; 9: 37 CrossRef MEDLINE PubMed Central
e107.Skanjeti A, Castellano G, Elia BO, et al.: Multicenter semiquantitative evaluation of (123)I-FP-CIT brain SPECT. J Neuroimaging 2015; 25: 1023–9 CrossRef MEDLINE
e108.Bouwmans AE, Vlaar AM, Mess WH, Kessels A, Weber WE: Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson‘s disease: prospective cohort study in 196 patients. BMJ Open 2013; 3: pii: e002613 CrossRef MEDLINE PubMed Central
e109.Ziebell M, Andersen BB, Thomsen G, et al.: Predictive value of dopamine transporter SPECT imaging with [¹²³I]PE2I in patients with subtle parkinsonian symptoms. Eur J Nucl Med Mol Imaging 2012; 39: 242–50 CrossRef MEDLINE
e110.Felicio AC, Godeiro-Junior C, Shih MC, et al.: Evaluation of patients with clinically unclear parkinsonian syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. J Neurol Sci 2010; 291: 64–8 CrossRef MEDLINE
e111.Vlaar AM, de Nijs T, van Kroonenburgh MJ, et al.: The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurol 2008; 8: 42 CrossRef MEDLINE PubMed Central
e112.Tolosa E, Borght TV, Moreno E, Uncertain DC: Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord 2007; 22: 2346–51 CrossRef MEDLINE
e113.Plotkin M, Amthauer H, Klaffke S, et al.: Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm (Vienna) 2005; 112: 677–92 CrossRef MEDLINE
e114.Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J: How useful is [123I] beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 2005; 76: 1211–6 CrossRef MEDLINE PubMed Central
e115.Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K: (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004; 61: 1224–9 CrossRef MEDLINE
e116.Lokkegaard A, Werdelin LM, Friberg L: Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002; 29: 1623–9 CrossRef MEDLINE
e117.Crotty GF, O‘Corragain OA, Bogue C, Crotty J, O‘Sullivan SS: The utility of dopamine transporter scans for diagnosing Parkinsonian disorders. Ir Med J 2018; 111: 751.
e118.Mirpour S, Turkbey EB, Marashdeh W, El Khouli R, Subramaniam RM: Impact of DAT-SPECT on management of patients suspected of Parkinsonism. Clin Nucl Med 2018; 43: 710–4 CrossRef MEDLINE
e119.Yomtoob J, Koloms K, Bega D: DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice. Parkinsonism Relat Disord 2018; 53: 37–41 CrossRef MEDLINE
e120.Graebner AK, Tarsy D, Shih LC, et al.: Clinical impact of 123I-ioflupane SPECT (DaTscan) in a movement disorder center. Neurodegener Dis 2017; 17: 38–43 CrossRef MEDLINE
e121.Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T: Is there a role for DAT-SPECT imaging in a specialty movement disorders practice? Neurodegener Dis 2015; 15: 81–6 CrossRef MEDLINE
e122.Covington MF, Sherman S, Lewis D, Lei H, Krupinski E, Kuo PH: Patient survey on satisfaction and impact of 123I-ioflupane dopamine transporter imaging. PLoS One 2015; 10: e0134457 CrossRef MEDLINE PubMed Central
e123.Sadasivan S, Friedman JH: Experience with DaTscan at a tertiary referral center. Parkinsonism Relat Disord 2015; 21: 42–5 CrossRef MEDLINE
e124.Thiriez C, Itti E, Fenelon G, et al.: Clinical routine use of dopamine transporter imaging in 516 consecutive patients. J Neurol 2015; 262: 909–15 CrossRef MEDLINE